Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Slides, webcasts and ePosters are available according to the presenters' agreement to release them. Abstracts are open access.
All registered delegates have access until 31 Mar 2022. ESMO Members who did not register will have access to all resources on 1st Dec 2021.
This series brings together all the relevant stakeholders who are developing each guideline, as well as those who are consulting and implementing them.
Latest, original data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
